10-Q: Prime Medicine Narrows Quarterly Loss, Boosts Cash with $138M Offering

Prime Medicine reported a reduced net loss for the quarter and significantly increased its cash position through a public offering, while advancing its gene editing pipeline and facing a legal dispute.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $50.6 million from $52.5 million in the prior year period.
• Total revenue for the three months ended September 30, 2025, increased to $1.2 million from $0.2 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $155.1 million, a slight increase from $153.6 million in the prior year period.
• Total revenue for the nine months ended September 30, 2025, increased to $3.8 million from $0.8 million in the prior year period.
• Cash, cash equivalents, and investments totaled $213.3 million as of September 30, 2025, excluding restricted cash.
• The company completed a public offering in August 2025, raising approximately $138.4 million in net proceeds by selling 43.7 million shares at $3.30 per share.
• The company expects its current cash, cash equivalents, and investments to fund operations into 2027.
• Research and development expenses increased by $3.7 million for the three months and $4.7 million for the nine months ended September 30, 2025, primarily due to facility expansion and license/IP costs, partially offset by workforce reduction.
• General and administrative expenses decreased by $2.9 million for the three months and $0.3 million for the nine months ended September 30, 2025, mainly due to workforce reduction.
• The company is strategically focusing its internal efforts on advancing its in vivo liver franchise (Wilson's Disease and AATD) and in vivo Cystic Fibrosis program, deprioritizing CGD programs.
• Positive Phase 1/2 trial data for PM359 in chronic granulomatous disease (CGD) showed 71% and 80% dihydrorhodamine positivity in two patients, exceeding potentially curative levels.
• An arbitration proceeding is ongoing with Beam Therapeutics, Inc. regarding the company's AATD program, with Beam alleging breach of agreement and trade secret misappropriation.

Sentiment

Score: 7

Explanation: The company demonstrated strong clinical progress with PM359 and successfully executed a substantial capital raise, significantly extending its cash runway. Quarterly net loss improved, and revenue saw a notable increase. However, the year-to-date net loss worsened, and the company faces an ongoing arbitration with Beam Therapeutics, Inc. and continues to project significant future operating losses, necessitating further capital raises. The strategic deprioritization of CGD programs, despite positive data, introduces a nuanced perspective on pipeline focus.

Positives

• Reduced net loss for the three months ended September 30, 2025, to $50.6 million from $52.5 million in the prior year.
• Significant increase in total revenue for both the three-month ($1.2 million vs $0.2 million) and nine-month ($3.8 million vs $0.8 million) periods ended September 30, 2025.
• Successful public offering in August 2025, raising $138.4 million in net proceeds, significantly bolstering the cash position.
• Cash, cash equivalents, and investments of $213.3 million (excluding restricted cash) are projected to fund operations into 2027.
• Positive Phase 1/2 clinical data for PM359 in chronic granulomatous disease (CGD), showing high dihydrorhodamine positivity (71% and 80%) exceeding potentially curative levels, with successful manufacturing and no serious adverse events.
• Received up to $24 million in additional funding from the Cystic Fibrosis Foundation (CFF) to accelerate development of Prime Editors for cystic fibrosis-related lung disease.
• Strategic focus on advancing in vivo liver franchise (Wilson's Disease and AATD) and the in vivo Cystic Fibrosis program.
• General and administrative expenses decreased for both the three-month and nine-month periods, partly due to workforce reduction.

Negatives

• Accumulated deficit reached $842.3 million as of September 30, 2025, indicating substantial historical losses.
• Net loss for the nine months ended September 30, 2025, increased slightly to $155.1 million from $153.6 million in the prior year.
• Research and development expenses increased for both the three-month ($43.99 million vs $40.34 million) and nine-month ($125.93 million vs $121.19 million) periods, driven by facility expansion and license/IP costs.
• The company expects to incur significant operating losses and negative operating cash flows for the foreseeable future.
• Deprioritization of CGD programs, despite positive clinical data for PM359, indicates a strategic shift away from this area.
• Ongoing arbitration with Beam Therapeutics, Inc. regarding the AATD program, with potential adverse outcomes including monetary damages or transfer of the program.

Risks

• Disruptions at the FDA, SEC, and other U.S. government agencies due to funding shortages or government shutdowns (e.g., current shutdown as of October 1, 2025) could hinder product development, approval, or commercialization.
• Unfavorable macroeconomic conditions, market volatility, high inflation, rising interest rates, international tariffs, and geopolitical developments could adversely affect business, financial condition, or results of operations.
• Proposed U.S. legislation (e.g., 2025 BIOSECURE Act) could restrict engagement with certain Chinese biotechnology companies, potentially impacting the ability to secure suppliers or service providers.
• The company will require additional funding beyond its current cash runway to continue research, identify product candidates, evaluate strategic alternatives, develop intellectual property, maintain collaborations, initiate clinical trials, and hire personnel. Inability to raise capital on favorable terms could negatively impact the business strategy.
• The ongoing arbitration with Beam Therapeutics, Inc. poses a risk of monetary damages or an order to cease work on and transfer the AATD program.
• Product candidates require significant additional R&D, preclinical and clinical testing, and regulatory approval, with no certainty of realizing significant revenue from product sales.
• Development by competitors of new technological innovations could impact the company's market position.
• Dependence on key personnel and the ability to attract and retain qualified employees.
• Reliance on third-party organizations for various aspects of operations.

Future Outlook

The company expects to incur significant operating losses and negative operating cash flows for the foreseeable future as it advances preclinical development, initiates clinical trials, and continues platform development. Current cash, cash equivalents, and investments are expected to fund operations into 2027. The company plans IND/CTA filings for Wilson's Disease in the first half of 2026 and for AATD in mid-2026. It will continue to pursue additional business development opportunities and plans regulatory interactions based on the current PM359 data set. A new registration statement on Form S-3ASR for the ATM Program is planned to be filed concurrently with this 10-Q.

Management Comments

• We continue to believe PM359 has the potential to transform the care of p47phox CGD.
• We are planning to have regulatory interactions based on the current data set.
• We intend to leverage the modularity of our platform to expeditiously and efficiently develop these programs supported by our universal liver lipid nanoparticle along with potential regulatory, clinical and other synergies from our modular technology.

Industry Context

The company operates in the highly competitive and capital-intensive biotechnology industry, specifically in gene editing. Its Prime Editing technology aims to offer a versatile and precise approach to genetic therapies. The strategic focus on in vivo liver diseases (Wilson's Disease, AATD) and cystic fibrosis aligns with a broader industry trend towards developing curative genetic treatments for severe inherited disorders. The collaboration with Bristol-Myers Squibb for CAR-T products and funding from the Cystic Fibrosis Foundation highlight the importance of partnerships in de-risking and accelerating development in this field. The ongoing arbitration with Beam Therapeutics underscores the intense intellectual property landscape and competitive pressures within gene editing. The mention of the BIOSECURE Act reflects increasing geopolitical and regulatory scrutiny on global biotech supply chains.

Comparison to Industry Standards

• PM359's Phase 1/2 trial data for CGD showed 71% dihydrorhodamine positivity by Day 60 in the first patient and 80% by Day 30 in the second patient, exceeding levels believed to be potentially curative.
• The trial also observed rapid neutrophil and platelet engraftment when compared to other commercially available autologous genetic therapy benchmarks.

Corporate Governance

Legal Proceedings

• Ongoing arbitration with Beam Therapeutics, Inc. regarding the company's AATD program.
• Beam alleges breach of collaboration agreement, failure to transfer technical information, trade secret misappropriation, and various business torts.
• Beam seeks declaratory, injunctive, and monetary relief, potentially including an order to cease work on and transfer the AATD program.
• The company filed its own arbitration demand seeking a declaration that its AATD program is within its defined field.
• The arbitrations have been consolidated and are in early stages.

Related Party Transactions

• Bristol-Myers Squibb (BMS): Collaboration revenue of $1.179 million for the three months and $3.748 million for the nine months ended September 30, 2025. Deferred revenue related party of $6.951 million (current) and $59.751 million (net of current) as of September 30, 2025. The Second Letter Agreement with Broad Institute modifies certain development milestones and related payment obligations under the BMS Collaboration Agreement.
• Beam Therapeutics, Inc. (Beam): Ongoing arbitration proceedings regarding the AATD program. The company holds a short-term investment in Beam equity securities, with a fair value of $4.861 million as of September 30, 2025.
• Cystic Fibrosis Foundation (CFF): Entered into an agreement in July 2025 for up to $24 million in additional funding. Received $6 million cash (Royalty Funding) and a $6 million equity investment (part of August 2025 offering). The company is obligated to return unused Royalty Funding and pay royalties/proceeds to CFF under certain conditions. This funding is recorded as a research and development funding liability ($18 million total, including $12 million from a 2024 agreement).
• The Broad Institute, Inc. (Broad): Entered into Fourth and Fifth Amendments to the License Agreement and a Second Letter Agreement in September 2025, modifying licensed patent applications and development milestones/payment obligations under the BMS Collaboration Agreement.

Stakeholder Impact

• Shareholders: Dilution from the August 2025 public offering (43.7 million shares issued). Potential for further dilution from future capital raises. Risk of adverse outcome in Beam arbitration could impact value. Positive clinical data for PM359 could increase value.
• Employees: Workforce reduction in May 2025. Stock option repricing aims to retain and incentivize employees.
• Customers/Patients: Advancement of Prime Editing technology and pipeline programs (Wilson's Disease, AATD, Cystic Fibrosis, CGD) offers potential for new curative genetic therapies.
• Collaboration Partners (BMS, CFF, Broad): Continued collaboration and funding agreements. The Beam arbitration could impact future collaborations or the AATD program.
• Creditors: The company's ability to raise additional capital and manage its operating losses will be critical for its long-term financial health.

Next Steps

• IND/CTA filings for Wilson's Disease in the first half of 2026.
• IND/CTA filings for Alpha-1 Antitrypsin Deficiency (AATD) in mid-2026.
• Regulatory interactions based on the current PM359 data set.
• Pursue additional business development opportunities to accelerate innovation and bolster financial resources.
• File a new registration statement on Form S-3ASR for the ATM Program concurrently with this 10-Q.
• Continue to raise additional capital through various financing mechanisms to support ongoing operations and growth strategy.

Key Dates

Recommendation

The company has demonstrated promising clinical data for PM359 and successfully secured substantial financing, extending its cash runway into 2027. This provides a solid foundation for advancing its core liver franchise programs. However, the year-to-date net loss increased, and the company faces an ongoing, potentially costly, legal dispute with Beam Therapeutics regarding a key program (AATD). The strategic deprioritization of CGD programs, despite positive data, introduces uncertainty about pipeline focus. Given the early stage of its primary programs, the high burn rate, and the legal overhang, a "hold" recommendation is appropriate. Investors should monitor the progress of the liver franchise, the outcome of the Beam arbitration, and future financing activities.

Keywords

Gene Editing, Prime Editing, Biotechnology, Clinical Trials, Wilsons Disease, Alpha-1 Antitrypsin Deficiency (AATD), Cystic Fibrosis, Chronic Granulomatous Disease (CGD), PM359, SEC Filing, 10-Q, Financial Results, Public Offering, Research and Development, Intellectual Property, Arbitration, Broad Institute, Cystic Fibrosis Foundation, Beam Therapeutics, Bristol-Myers Squibb